期刊文献+

LC-MS/MS法测定大鼠血浆中的罗哌卡因 被引量:1

Determination of ropivacaine in rat plasma with liquid chromatography-tandem mass spectrometry
下载PDF
导出
摘要 目的建立测定大鼠血浆中罗哌卡因的高效液相色谱串联质谱法。方法色谱柱为Agela MP C18(2.1 mm×50 mm,3μm)。采用电喷雾离子源(ESI)正离子多反应监测(MRM)扫描分析,罗哌卡因和内标(咪达唑仑)的检测离子分别为m/z 275.2/126.1和326.0/291.0。结果罗哌卡因的线性范围为0.5~250 ng/ml,相关系数r为0.9946,批内精密度为1.32%~6.74%,基质效应在95.5%~102.6%,回收率为89.8%~104.7%。结论本法操作简单、方法准确可靠、检测灵敏度高,可用于罗哌卡因大鼠体内的药代动力学研究。 Objective To develop an LC-MS/MS method for the determination of ropivacaine in rat plasma. Methods The chromatographic separation was achieved on an Agela MP C18(2.1 mm×50 mm,3 μm)analytical column. The multiple reaction monitoring(MRM)mode of the positive ion was adopted in the MS detection,and the precursors to the product ion transitions of m/z 275.2/126.1and 326.0/291 were used to measure ropivacaine and internal standard(midazolam). Results The method was linear over the ropivacaine concentration range of 0.5-250 ng/ml with the correlation coefficients r of 0.9946. The average inter-day precision values(RSD)were 1.32%-6.74%,the matrix effect values were 95.5%-102.6% and the average recovery values were 89.8%-104.7%. Conclusion The analysis methods for ropivacaine are simple,accurate and sensitive,thus can be used for the pharmacokinetic research of ropivacaine incorporated cubic liquid crystal in rat.
出处 《国际药学研究杂志》 CAS CSCD 北大核心 2016年第4期736-739,共4页 Journal of International Pharmaceutical Research
关键词 LC-MS/MS 罗哌卡因 大鼠 血浆 LC-MS/MS ropivacaine rat plasma
  • 相关文献

参考文献8

  • 1Rossi S. Australian Medicines Handbook [ M ]. sydney: Taylor & Francis, 2006:112-119.
  • 2Roy SD, Gutierrez M, Flynn GL. Controlled transdermal deliv- ery of fentanyl: characterizations of pressure-sensitive adhe- sives for matrix patch design [J]. J Pharm Sci, 1996, 85 (5) : 491-495.
  • 3Monika SK, Wolfgang M, Hans-Christian K. Lipid nanoparti- cles for improved topical application of drugs for skin diseases [J]. Adv Drug Deliv Rev , 2007, 59: (59)427-443.
  • 4Souto EB, Wissing SA, Barbosa CM. Development of a con- trolled release formulation based on SLN and NLC for topical clotrimazole delivery[J], lnt JPharm, 2004, 278(1):71-77.
  • 5Langley MS, Heel RC, Transdermal clonidine. A preliminary re- view of its pbarmacodynamic properties and therapeutic efficacy [J]. Drugs, 1988, 35(2): 123-142.
  • 6Scott DB, Lee A, Fagan D. Acute toxicity of ropivacaine com- pared with that of bupivaeaine[J]. Anesth Analg, 1989, 69(5) : 563-569.
  • 7李慧博,张现化,姜天乐,郭向阳,赵荣生.LC-MS/MS法测定全膝关节置换术患者血浆中罗哌卡因的浓度及局部给药的安全性[J].中国临床药理学杂志,2014,30(3):212-215. 被引量:7
  • 8李雪宁,许剑安,陈伟力,徐红蓉,缪长虹.LC-MS/MS法测定手术患者中罗哌卡因注射液的血浓度及药动学[J].中国临床药学杂志,2006,15(5):283-286. 被引量:7

二级参考文献13

  • 1王平全,陆国红,周贤飚,沈金芳,陈曙霞,梅尚文,陈美芳.苦参碱的人体药代动力学[J].药学学报,1994,29(5):326-329. 被引量:24
  • 2Markham A, Faulds D. Ropivacaine. A review of its pharmacology and therapeutic use in regional anaesthesia[J]. Drugs, 1996,52: 429 - 449.
  • 3Simpson D, Curran MP, Oldfield V, et al. Ropivacalne: a review of its use in regional anaesthesia and acute pain management [ J ]. Drugs, 2005,65:2675 -2717.
  • 4Leone S, Di Cianni S, Casati A, et al. Pharmacology, toxicology, and clinical use of new long acting local anesthetics, repivacaine and levobupivacaine [ J ]. Acta Biomed, 2008,79:92 - 105.
  • 5Berend KR, Lembardi AV Jr, Mallory TH. Rapid recovery protocol for peri - operative care of total hip and total knee arthroplasty pa- tients[ J]. Surg Technol lnt, 2004,13:239 - 247.
  • 6Cobb Z, Andersson LI. Determination of repivacaine in human plas- ma using highly selective molecular imprint - based solid phase ex- traction and fast LC- MS analysis[J]. Anal Bioanal Chem, 2005, 383:645 - 650.
  • 7Kawata T, Homma M, Kakiuchi Y, eta/. Liquid chromatographic de- termination of plasma ropivacaine for assessing pharmacokinetics of the viscous preparation[ J ]. Biol Pharm Bull, 2005,28:2271 - 2273.
  • 8Mathieu O, Hillaire- Buys D, Dadure C, et al. Liquid chromatog- raphy - electrospray mass spectrometry determination of free and to- tal concentrations of repivacaine in human plasma [ J ]. J Chroma- togr B Analyt Technol Biomed Life Sci, 2006,831:91 -98.
  • 9Kuthiala G, Chaudhary G. Ropivacaine: A review of its pharmacol- ogy and clinical use[J]. Indian J Anaesth, 2011,55:104 - 110.
  • 10Wulf H, Worthmann F, Behnke H, et al. Pharmacokineties and pharmacodynamics of repivacaine 2 mg/mL, 5 mg/mL, or 7. 5 mg/mL after ilioinguinal blockade for inguinal hernia repair in a- dults [ J ]. Anesth Analg, 1999,89 : 1471 - 1474.

共引文献12

同被引文献7

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部